Last updated: July 23, 2026
Supernus Pharmaceuticals, Inc. v. Lupin Limited (1:21-cv-01293): Litigation Summary, Claims at Issue, and Patent-Strength Implications
Executive summary: Supernus Pharmaceuticals’ suit against Lupin (case no. 1:21-cv-01293) targets Lupin’s proposed generic entry for a Supernus-marketed branded product. The posture is a federal Hatch-Waxman patent infringement dispute tied to Orange Book-listed patents for the asserted drug, with Supernus seeking to block market launch and/or secure a negotiated entry settlement. The litigation is best analyzed through (1) which patents were asserted, (2) Lupin’s defenses (invalidity and non-infringement), (3) whether the case reached claim construction and/or summary judgment, and (4) any settlement that would control launch timing.
Actionable bottom line: The commercial risk for Lupin is driven by whether Supernus’ asserted patents include core composition/formulation claims versus narrow method-of-use or manufacturing claims. If the asserted estate is composition/formulation-heavy, the probability of design-around and easy invalidity wins drops, increasing the likelihood of a settlement with an earlier or later “skinny launch” carve-out.
What patents are asserted in Supernus v. Lupin (1:21-cv-01293)?
Featured-snippet answer: The asserted patents are the Orange Book-listed patents for the relevant Supernus branded drug that Supernus identified in its infringement complaint tied to Lupin’s ANDA certification.
How the complaint typically maps to Hatch-Waxman practice
- Asserted patent categories usually include:
- Composition/formulation claims for active ingredient or drug product.
- Method-of-use claims if the Orange Book listings include use patents (less common than formulation for many CNS products, but it depends on the product history).
- Drug delivery system claims if the product is controlled release or has a specialized delivery mechanism.
- ANDA linkage: Supernus’ complaint is tied to Lupin’s Paragraph IV filing and/or a challenge to specific Orange Book listings, with infringement alleged against the proposed generic product.
Patent-strength lens to apply once the asserted list is identified
- Composition and formulation claims
These are harder to design around because changing ingredients, ratios, or release characteristics can still land within claim scope.
- Method-of-use claims
These create litigation leverage because non-infringement defenses often turn on proposed labeling and whether the generic’s label induces the patented use.
- Process/manufacturing claims
These are often litigated through manufacturing disclosures and expert testimony on process equivalency.
Litigation documents to locate the asserted patents
- Complaint (Dkt. entry) usually lists each asserted patent by number, title, and claim subset.
- Rule 16 scheduling order often signals which issues are prioritized (claim construction, discovery scope, summary judgment plan).
- Markman materials (if held) indicate claim interpretation disputes.
(This analysis framework is the same across Supernus’ Hatch-Waxman cases; the case-specific asserted patent list is determinative.)
What defenses does Lupin raise in Supernus v. Lupin (1:21-cv-01293)?
Featured-snippet answer: Lupin’s typical defenses in Paragraph IV Hatch-Waxman suits are non-infringement and invalidity (anticipation, obviousness, lack of written description/enablement, indefiniteness, and prosecution history estoppel where relevant).
Non-infringement pathways
- Literal infringement: Lupin argues the proposed generic product does not meet each claim limitation.
- Doctrine of equivalents: Lupin challenges equivalence on substantial differences in formulation parameters, release profile, or performance metrics.
- Labeling/inducement: For method-of-use claims, Lupin argues the proposed FDA label does not direct performance of the patented method.
Invalidity pathways
- Anticipation (35 U.S.C. §102): prior art disclosures of the same formulation/method/use.
- Obviousness (35 U.S.C. §103): combinations of prior art and routine optimization arguments.
- Enablement/written description (35 U.S.C. §112): whether the patent specification supports the breadth of the asserted claims.
- Indefiniteness (35 U.S.C. §112(b)): if claims use functional language without objective boundaries.
Practical impact
- If Lupin’s invalidity case focuses on obviousness through predictable formulation tweaks, the outcome often turns on whether Supernus can show the formulation achieved non-obvious results or solved a recognized problem with evidence of unexpected performance.
- If Lupin’s case relies on design-around freedom (different release mechanism or different active salt form), the question becomes whether the asserted claims are broad enough to capture those alternatives.
Timeline: When did Supernus sue Lupin, and what launch date risk does the case create?
Featured-snippet answer: In Hatch-Waxman, timing is anchored to:
- ANDA filing date and the date Supernus received notice of Lupin’s certification,
- complaint filing within the statutory period,
- the 30-month stay trigger (if applicable),
- and any settlement terms lifting/adjusting launch constraints.
Key decision points that drive exclusivity and entry risk
- Filing of complaint and service
Sets the enforcement runway.
- 30-month stay (if triggered)
Determines the maximum time before a generic can launch absent a patent bar/settlement.
- Claim construction (Markman)
Often determines whether Supernus’ claims read broadly enough to capture Lupin’s product.
- Summary judgment / trial
If reached, sets a clear result; if not, settlements commonly resolve.
What to infer from posture
- If the case proceeded through substantive motions, then the asserted patents are likely to have survived early dismissal and remain at issue in claim construction.
- If the case settled early, it likely reflects the parties’ assessment that one side’s positions were strong enough to justify a negotiated outcome.
How strong is the patent estate in Supernus v. Lupin (1:21-cv-01293)?
Featured-snippet answer: Strength depends on whether Supernus asserted patents include high-impact Orange Book listings that are hard to avoid and not easily invalidated based on the closest prior art.
Strength indicators used in infringement analysis
- Number of asserted patents: more asserted patents generally correlates with more litigation leverage, especially if they span different claim types.
- Claim breadth: broad claims increase capture risk for Lupin’s design choices.
- Remaining term: if patents have meaningful remaining life, the economic pressure is higher.
- Prior litigation history: if Supernus’ patents have already been litigated and upheld, that can signal survivability.
Litigation leverage signals
- Claim charts showing multiple independent grounds for infringement often push defendants toward settlement.
- If Lupin concedes infringement on some claims but disputes others, the likely outcome is partial settlement and/or “carve-out” design changes.
Did Supernus and Lupin reach a settlement that controls generic entry?
Featured-snippet answer: In most Paragraph IV Hatch-Waxman disputes, settlement is the dominant mechanism to control entry timing when both sides find trial risk material. The settlement terms, if entered, determine launch timing, design-around scope, and payment or royalty structure.
Settlement clause categories that matter for commercial planning
- Agreed launch date for Lupin (or prohibition period).
- Market entry restrictions tied to specific formulations, dosage strengths, or release profiles.
- Narrowing admissions for later litigation (rarely public in full detail).
- Dismissal of claims and mutual covenant not to sue.
(A case-specific answer requires the docket settlement entry and/or court order terms; without that record, no definitive settlement date or scope can be stated.)
What is the Orange Book status of the relevant Supernus drug in this case?
Featured-snippet answer: The Orange Book status is the source for which patents are asserted and whether Lupin’s ANDA must satisfy specific certifications (Paragraph I, II, III, IV) for each listing.
How to read Orange Book status for litigation planning
- If the asserted patents are expiring soon: settlement economics shift toward earlier entry.
- If multiple patents are still listed: risk increases because even if one patent falls, others can still block launch.
- If patents are tied to specific strengths or dosage forms: Lupin’s entry may be partial unless it also covers the other strengths/dosage forms.
How does this dispute compare with other Supernus Hatch-Waxman fights against generics?
Featured-snippet answer: Supernus’ enforcement posture in similar suits typically targets both formulation robustness and method-of-use labeling controls, with settlement often structured around a controlled launch window.
Comparative factors
- Which claim types were asserted (composition/formulation vs method-of-use).
- Whether the proposed generic uses the same release profile or dosage form.
- Whether the case proceeded to claim construction.
- Whether the court issued substantive rulings affecting patent scope or claim interpretation.
What generic entry risks exist for Lupin if Supernus’ patents are upheld?
Featured-snippet answer: If Supernus prevails on infringement (or invalidity defenses fail), Lupin faces either:
- a launch delay until patent expiry, or
- a settlement-imposed entry date and potential product design constraints.
Commercial risk drivers
- Patent survival across multiple listings: even if one patent is invalidated, other asserted Orange Book patents may remain.
- Design-around feasibility: if claims cover essential formulation parameters, alternatives may not be workable.
- Labeling constraints: for method-of-use patents, labeling changes can reduce infringement risk but can also impair market uptake.
What FDA pathway factors influence this litigation’s outcomes?
Featured-snippet answer: FDA regulatory posture influences the regulatory timeline but not the core legal infringement/validity analysis. The practical effect is on how quickly Lupin can launch once legal barriers are cleared.
Key pathway elements
- ANDA approval status: whether Lupin received final approval or only tentative approval.
- Patent certification status: each Orange Book listing ties to a separate legal barrier.
- Potential 505(j) stay: governed by the timing and procedural posture of the litigation.
Key procedural milestones: What to look for in the docket for 1:21-cv-01293
Featured-snippet answer: The case’s IP outcome is determined by the procedural record: asserted patents, claim construction, dispositive motions, and any settlement/order entries.
Docket checkpoints that indicate likely settlement vs trial
- Early filings:
- responsive pleadings,
- Rule 12 motions (dismissal) if any,
- infringement/non-infringement and invalidity contentions.
- Markman:
- claim construction hearing dates and order.
- Dispositive stage:
- summary judgment filings.
- Resolution:
- stipulation of dismissal,
- consent judgment,
- settlement order.
Key Takeaways
- The case 1:21-cv-01293 is a Hatch-Waxman patent infringement dispute in which Supernus asserts Orange Book-listed patents against Lupin’s proposed generic entry.
- The commercial leverage is driven by whether the asserted estate is concentrated in composition/formulation claims (higher design-around difficulty) or method-of-use claims (labeling-dependent infringement).
- Launch risk for Lupin is determined by (1) which patents remain enforceable after claim construction, (2) the validity posture (anticipation/obviousness strength), and (3) any settlement entry terms or court timing rulings.
- The decisional record that matters most is the asserted patent list and procedural milestones (Markman, summary judgment, dismissal/settlement).
FAQs
- What is the 30-month stay impact in Hatch-Waxman litigation like Supernus v. Lupin (1:21-cv-01293)?
- Can Lupin avoid infringement by changing formulation parameters or release profile in an ANDA Paragraph IV case?
- How do method-of-use patents change infringement analysis compared with composition/formulation patents?
- What docket events signal whether the case will go to trial versus settle in Hatch-Waxman disputes?
- How does claim construction typically affect settlement leverage in generic patent litigation?
References
- U.S. District Court docket, Supernus Pharmaceuticals, Inc. v. Lupin Limited, 1:21-cv-01293. (Case docket entries).
